Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Treating patients with type 1 diabetes with a certain antihypertensive drug
preserve cerebral function during hypoglycaemia.
Background: Studies have found that certain genetic variations leaves a subject with type 1
diabetes more prone to hypoglycaemia. It it thought to be a decline in cognition during
hypoglycaemia that leaves them at risk of severe hypoglycaemia. The idea is tha when you
suppress the genetic phenotype with a well known antihypertensive drug an improvement in
cognition will occur and this will remove the patients tendency to severe hypoglycaemia.
Methods: The investigators want to explore whether the cerebral function is improved during
hypoglycaemia in subjects with type 1 diabetes and the above mentioned genetic variation when
treated with the antihypertensive drug Candesartan.
Phase:
N/A
Details
Lead Sponsor:
Louise Faerch
Treatments:
Angiotensin II Angiotensin Receptor Antagonists Angiotensinogen Candesartan Candesartan cilexetil Giapreza